

Review Form 1.6

Journal Name:	Asian Journal of Research in Cardiovascular Diseases
Manuscript Number:	Ms_AJRCD_94295
Title of the Manuscript:	Antihypertensive efficacy and safety of the fixed-dose combination of Efonidipine and Chlorthalidone in Indian patients
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<https://www.journalijrc.com/index.php/AJRCD/editorial-policy>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	<p>MATERIAL AND METHODS:</p> <ol style="list-style-type: none"> 1. There is no information regarding the methodology of how the patients were randomized to the two treatment groups. 2. The number of patients on previous antihypertensive medication and number of patients who were newly diagnosed hypertensives have not been mentioned. Has stratified randomization of patients to the two treatment groups done based on previous antihypertensive medication? 3. There is no information regarding methods adopted in the study to minimize the possibility of bias (double blind study has been mentioned in the abstract but not in the article thereafter). 4. Were the two treatment groups matched for gender? If not, were there any reasons for not doing so? 5. What was the antihypertensive treatment plan adopted post completion of the clinical trial? 	
Minor REVISION comments	<p>INTRODUCTION:</p> <ol style="list-style-type: none"> 1. Paragraph 1 Sentence 2 in introduction 'Hypertension, a leading cause of CVD, is defined as having a blood pressure (BP) of at least 130/80 mm Hg' may be modified to enhance clarity. 2. Paragraph 4 Sentence 2 'The newly published American Heart Association (AHA)/American College of Cardiology (ACC)/Centers for Disease Control (CDC) algorithm for high blood pressure management also recommends a thiazide diuretic/CCB combination for patients not controlled with a monotherapy and as a first-line therapy'. Not referenced. Reference may be added. <p>DISCUSSION:</p> <ol style="list-style-type: none"> 1. The discussion is focussed on the advantages of fixed dose combinations and that of CCB/thiazide (-like) diuretic combination in general. However, the same advantages are also relevant to the control drug. There is no mention about whether the new drug has any specific advantages. The pharmacological aspects of Efonidipine have not been included in the discussion, though briefly touched upon in the introduction. Relevant clinical studies related to efonidipine, if any, could have been included in the discussion. This could provide for context to the findings of this study. 	
Optional/General comments	The introduction (810 words) is longer than the discussion (761 words), which is unusual for a research publication. The same may be addressed, if possible, without distorting the overall structure of the article.	

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

[Review Form 1.6](#)

Reviewer Details:

Name:	Supratim Datta
Department, University & Country	Sikkim Manipal Institute of Medical Sciences, Sikkim Manipal University, India